Patient target groups

Thumbs up from the international guidelines

International guidelines1-8 encourage health professionals to consider plant stanol ester, the functional ingredient in Benecol® foods and food supplements, as part of the management of raised cholesterol especially for the following three patient groups:

  1. Individuals with high LDL cholesterol at low or intermediate cardiovascular risk who do not qualify for statin therapy

  2. High and very high risk patients, such as patients with diabetes, who fail to reach their LDL-cholesterol targets on statins alone, or are statin intolerant

  3. Adults and children with familial hypercholesterolemia

When consumed in sufficient amounts as part of daily meals plant stanol ester lowers LDL cholesterol in 2-3 weeks by 10%, on average, and keeps it at the lower level.

So when helping your patients to manage their cholesterol, adding Benecol® foods or food supplements to their diets is the right thing to do.

Meet the patients and watch their stories below.

 

References

  1. Gylling et al. EAS Consensus Paper. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014; 232: 346-360. http://www.atherosclerosis-journal.com/article/S0021-9150(13)00694-1/pdf
  2. Catapano et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 2016; 253: 281-344. http://www.atherosclerosis-journal.com/article/S0021-9150(16)31267-9/pdf
  3. Piepoli et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315–2381. http://eurheartj.oxfordjournals.org/content/ehj/37/29/2315.full.pdf
  4. International Atherosclerosis Society. IAS Position Paper: Global Recommendations for the Management of Dyslipidemia, 2013. http://www.athero.org/IASPositionPaper.asp
  5. American Diabetes Association. Cardiovascular disease and risk management. Sec. 8. In Standards of Medical Care in Diabetes 2016. Diabetes Care 2016; 39: S60–S71.  http://care.diabetesjournals.org/content/diacare/39/Supplement_1/S60.full.pdf
  6. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics 2011; 128: S213 -S256. https://www.nhlbi.nih.gov/files/docs/peds_guidelines_sum.pdf
  7. Nordestgaard et al. EAS Consensus Paper. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Eur Heart J 2013; 34 (45): 3478-3490. http://eurheartj.oxfordjournals.org/content/ehj/34/45/3478.full.pdf
  8. Stroes et al. EAS Consensus Paper. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36 (17): 1012-1022.  http://eurheartj.oxfordjournals.org/content/ehj/36/17/1012.full.pdf

歡迎瀏覽供醫療專業人員的倍樂醇®網站

你會從這裡找到關於倍樂醇®產品如何降低膽固醇的資訊及其科學證據。倍樂醇產品經臨床實驗證明,能降低平均10%的總膽固醇和高密度脂蛋白膽固醇。倍樂醇產品含有添加植物甾烷醇酯成分,這種成分被廣泛推薦於管理血脂異常的指引。

我是一個專業醫護人員。請繼續»

 

我不是一個醫療專業人員,但我想知道更多關於倍樂醇產品的資訊»

 

倍樂醇®能快速見效及使膽固醇自然地保持在較低的水平!